WorksheetsEuthyrox New Formulation (NF) Communication Plan
Total questions: 14
Worksheet time: 35mins
Name
Class
Date
1.
What is DHCP letter?
a)
It is a letter to inform HCPs about the benefits of Euthyrox tablets in managing hypothyroidism.
b)
It is a packaging change letter to update HCPs about the pricing and packaging change of Euthyrox.
c)
It is a patient information letter to inform patients about Euthyrox NF and the guidance of switching to new formulation.
d)
It is ‘Dear HCP’ letter to inform doctors and pharmacists about Euthyrox NF and the monitoring guidance of patient switching between tablets.
2.
When is Euthyrox NF 50mcg estimated to be available in Malaysia?
a)
August 2020
b)
September 2020
c)
July 2020
d)
November 2020
e)
June 2020
3.
Which of the following is FALSE about Euthyrox NF?
a)
Euthyrox NF offers improved stability of the active substance throughout the whole shelf life.
b)
Euthyrox NF has modified excipients with mannitol and citric acid.
c)
Euthyrox NF is without lactose.
d)
Euthyrox NF’s efficacy and safety profile are not the same as old formulation.
4.
When is Euthyrox NF 25mcg estimated to be available in Malaysia?
a)
August 2020
b)
September 2020
c)
July 2020
d)
November 2020
e)
June 2020
5.
Which of the statement is FALSE about the switching to Euthyrox NF?
a)
Euthyrox NF should be taken in the same manner as Euthyrox old formulation.
b)
Close monitoring of patients switching to Euthyrox NF is recommended as thyroid imbalances can be triggered by the switch due to levothyroxine’s narrow therapeutic range.
c)
Particular attention should be paid to vulnerable groups (e.g. patients with thyroid cancer, cardiovascular disease, pregnant women, children, and the elderly).
d)
After switching to new formulation, patient’s individual daily dose remains appropriate should be confirmed using clinical and laboratory assessments.
e)
Patients can switch back to Euthyrox old formulation even after they have started taking Euthyrox NF.
6.
When is Euthyrox NF 100mcg estimated to be available in Malaysia?
a)
August 2020
b)
September 2020
c)
July 2020
d)
November 2020
e)
June 2020
7.
What should the prescribing physicians do when patient is switching to Euthyrox NF? (You may select more than 1 answer)
a)
Ensure that patients are sufficiently informed about the formulation and packaging changes using patient information sheet (PIS).
b)
Confirm that the patient’s individual daily dose remains appropriate using clinical and laboratory assessments.
c)
If necessary, adjust the dosage following the patient's clinical response and laboratory test.
8.
What should pharmacists do when patient is switching to Euthyrox NF? (You may select more than 1 answer)
a)
Advise patients to take Euthyrox NF tablets exactly the same way as Euthyrox old formulation tablets.
b)
Advise patients to seek medical advice on the need of close monitoring when switching between tablets.
c)
Advise patients not to change back to Euthyrox old formulation tablets once they have started with Euthyrox NF tablets.
d)
Provide patients with the patient information sheet (PIS).
e)
Before switching, the patients must be aware with the formulation and packaging changes.
9.
Which of the following is FALSE about PIS letter?
a)
It is the patient information sheet to be distributed by doctors and pharmacists.
b)
It is used to inform the patients about the changes of Euthyrox NF and guidance of switching to Euthyrox NF.
c)
It is letter to inform doctors and pharmacists about the changes of Euthyrox NF.
d)
It is a letter to ensure patients are aware with the changes of the new formulation and what they should be aware upon switching to Euthyrox NF.
10.
What are the changes of the Euthyrox NF? (You may choose more than 1 answer)
a)
Changes in tablet size and available strengths, therefore patient should be aware with the different way of taking Euthyrox NF.
b)
Different active substance (levothyroxine) from different manufacturer.
c)
Optimization of the formulation intended to ensure that the content of active substance, which is levothyroxine, is more constant during the entire shelf life of the product.
d)
Elimination of lactose.
11.
What should the patient be aware when the pharmacist gives the Euthyrox NF for the first time? (You may choose more than 1 answer)
a)
Check the name and strength of the medicine as the new box and blister of Euthyrox NF have changed colours.
b)
Take Euthyrox NF in the same way as the old formulation.
c)
Contact doctor to clarify if TSH level needs to be checked after starting the new formulation.
d)
Once patient has started Euthyrox NF, patient is advised not to change back to old formulation.
e)
If patient is planning to travel, make sure to take enough medication of the same formulation.
12.
Which of the statement is FALSE about Euthyrox NF?
a)
No change in the overall safety profile is expected.
b)
The active ingredient is still levothyroxine sodium, from the same source. Only the excipients have been changed (lactose has been replaced by mannitol, and citric acid has been added).
c)
Clinical studies have confirmed that the new excipients do not change the quantity of active substance that enters the blood or how quickly it reaches the target organ. This ensures that the efficacy and safety are the same as in the old formulation.
d)
The uptake of the active substance is the same for all individuals.
13.
Following are the possible thyroid imbalance symptoms that patient should be aware upon switching to Euthyrox NF, EXCEPT:
a)
Symptoms related to hypothyroidism (low thyroid level), e.g. unusual tiredness, constipation, and a general feeling of slowing down.
b)
Symptoms related hyperthyroidism (high thyroid level), e.g. sweating, tachycardia (fast heart rate), palpitations and agitation.
c)
Symptoms related to respiratory tract problem, e.g. fever, coughing, shortness of breath, persistent pain or pressure in the chest and bluish lips or face.
14.
Below are the changes of the Euthyrox NF’s box and blister, EXCEPT:
a)
The text ‘Modified excipients’ is printed on the box and the blister of the new formulation.
b)
The layout of the box has changed to a new magenta design with butterfly logo.
c)
The colours of the company logo will be modified.
d)
The change to the layout of the blister.
e)
The change of packing size.
100 %
